Market openADR

Novo Nordisk/$NVO

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Novo Nordisk

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Ticker

$NVO
Sector
Health Care

Trading on

NYSE

Industry

Pharmaceuticals

Headquarters

Bagsvaerd, Denmark

Employees

76,826
Website
www.novonordisk.com

Novo Nordisk Metrics

BasicAdvanced
$355B
23.97
$3.29
0.19
$1.03
1.99%
$355B
0.19
$148.15
$77.82
8.3M
$1.03
0.74
0.523
62.497
71.636
43.71%
85.29%
21.47%
80.78%
23.974
8.322
17
75.31
34.695
1.30%
1.99%
25.03%
21.54%
27.29%
29.71%
29.91%

What the Analysts think about Novo Nordisk

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Novo Nordisk stock.

Novo Nordisk Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Novo Nordisk Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

Novo Nordisk News

AllArticlesVideos
Novo Nordisk A/S Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - NVO

Novo Nordisk A/S Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - NVO

Accesswire·15 minutes ago
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 25, 2025 in Novo Nordisk A/S Lawsuit - NVO

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 25, 2025 in Novo Nordisk A/S Lawsuit - NVO

Accesswire·2 hours ago
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk

INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk

GlobeNewsWire·2 hours ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $NVO

$
Sign up or log in to buy
Capital at risk
Market openADR

Upcoming events

Mar31
Novo Nordisk
Dividend·Ex-dividend
Apr8
Novo Nordisk
Dividend·Payment
$1.099206
Per share
FAQs

What’s the current market cap for Novo Nordisk stock?

Novo Nordisk (NVO) has a market cap of $355B as of March 11, 2025.

What is the P/E ratio for Novo Nordisk stock?

The price to earnings (P/E) ratio for Novo Nordisk (NVO) stock is 23.97 as of March 11, 2025.

Does Novo Nordisk stock pay dividends?

Yes, the Novo Nordisk (NVO) stock pays dividends to shareholders. As of March 11, 2025, the dividend rate is $1.02575 and the yield is 1.99%. Novo Nordisk has a payout ratio of 43.71% on a trailing twelve-month basis.

When is the next Novo Nordisk dividend payment date?

The next Novo Nordisk (NVO) dividend payment is scheduled for April 08, 2025.

What is the beta indicator for Novo Nordisk?

Novo Nordisk (NVO) has a beta rating of 0.19. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.